anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with SNCA whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Early Onset Parkinson&#39;s Disease (PARK1). Also provided are materials and methods for editing a SNCA gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a SNCA gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a SNCA gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a SNCA gene. In addition, the present disclosure provides therapeutics for treating patients with a SNCA related condition or disorder.
PURPOSE:To obtain a curing agent for xerophthalmia containing a spirooxathiolanequinuclidine derivative or its acid adduct as an active component, free from a side effect and having extremely low toxicity. CONSTITUTION:This curing agent for xerophthalmia contains a spirooxathiolanequinuclidine derivative of formula I (R&lt;1&gt; and R&lt;2&gt; are each H, an alkyl, a cyclopentyl, a cyclohexyl, an aryl, a diarylmethylol or an alkyl substituted by one or more than one aryl group) or its acid adduct as an active component and capable of being topically administered by instillation. As a compound of formula I, a salt of 2-methylspiro(1,3-oxathiolane-5,3&#39;)quinuclidine hydrochloric acid adduct is especially preferable. The compound of formula I is obtained e.g. by reacting 3-hydroxy-3-mercaptomethylquinuclidine with a carbonyl compound of the formula R&lt;1&gt;-CO-R&lt;2&gt;. This curing agent can accelerate lacrimation by stimulating a muscarine M3 receptor.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a methylmercaptan-deodorizing agent having excellent methylmercaptan-deodorizing activities and palatability, and to provide a foul breath inhibitor and a composition for the oral cavity.  &lt;P&gt;SOLUTION: The methylmercaptan-deodorizing agent (foul breath inhibitor) comprises an extract of Terminalia belerica. The aspect wherein the extract of the Terminalia belerica is an extract of the skin of the fruit of the Terminalia belerica, the aspect wherein the extract of the Terminalia belerica is a water extract, and the like are preferable. The composition for the oral cavity contains the methylmercaptan-deodorizing agent. The aspect wherein the concentration of a solid product of the extract of the Terminalia belerica in the composition for the oral cavity is ≥0.0025 mass%, and the like, are preferable.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a new DNA for producing a protein having activity of supporting or promoting differentiation and maturation of osteoclast, useful for a medicine for treating bone dysbolism, a reagent for study, etc., comprising a genome DNA encoding the protein. SOLUTION: This new genome DNA encodes a protein having the following physicochemical properties. Affinity: specifically combining with an osteoclastogenesis inhibitory factor(OCIF), having a high affinity (dissociation constant on a cell membrane, kd value is &lt;=10-9). Molecular weight: about 30,000-40,000 by molecular weight measurement by SDS polyacrylamide electrophoresis under a nonreducing condition. Bioactivity: having activity of supporting or promoting differentiation or maturation of osteoclast by coculture of mouse osteoblast-like stroma cell and mouse splenocyte in the presence of bone resorption promoting factor such as activated vitamin D3 and parathormone, etc. The genome DNA is useful as a prophylactic and a therapeutic agent for bone dysbolism such as osteoporosis, etc.
The invention belongs to an oral Chinese herbal preparation for treating post-traumatic brain syndrome, and the oral Chinese herbal preparation is a human medicinal product. The preparation is prepared from the following Chinese herbs in parts by weight: 10+/-2 parts of Astragalus mongholicus, 10+/-2 parts of American ginseng, 10+/-2 parts of Angelica sinensis, 10+/-2 parts of medlar, 10+/-2 parts of the root of red-rooted salvia, 10+/-2 parts of ligusticum wallichii, 10+/-2 parts of root of common peony, 10+/-2 parts of peach kernel, 10+/-2 parts of Poria cocos, 10+/-2 parts of pericarpium citri reticulatae, 10+/-2 parts of plantain seed, 10+/-2 parts of tabasheer, 10+/-2 parts of rhizoma acori graminei, 10+/-2 parts of gastrodia elata, 10+/-2 parts of uncaria, 10+/-2 parts of spina date seed, 10+/-2 parts of amber powder and 6+/-1.2 parts of honey-fried licorice root. Clinical effect observation proves that the total effective rate of the oral Chinese herbal preparation to the oral traditional Chinese medicine preparation is 94.07%, and has better treatment effect (P&lt;0.01) compared with Western medicines such as Rotundine, piracetam, oryzanol and nimodipine for treating post-traumatic brain syndrome. Moreover, the Chinese herbal preparation has no obvious toxic or side effect, and can be taken for a long time. The dose of the preparation is small, and effective medicinal components are easy to release, can be absorbed quickly and can fully play the pharmaceutical effect. The preparation is convenient to carry, easy to take and beneficial to large-scale production.
An isolated nucleic acid molecule consists of genomic DNA encoding a MAGE-B gene consisting of: a) nucleotides 3266-7979 of SEQ ID NO:15; b) nucleotides 23546-25194 of SEQ ID NO:15; c) nucleotides 29748-31474 of SEQ ID NO:15; d) nucleotides 29748-31827 of SEQ ID NO:15 or e) nucleotides 31403-39691 of SEQ ID NO:15.  An isolated nucleic acid molecule encodes a MAGE-B1 variant, consisting of, in 5&#39; to 3&#39; order: f) nucleotides 31403-31474, 33958-34062, 35057-35139 and 38088-39691 of SEQ ID NO:15; g) nucleotides 31403-31474, 33958-34062, and 38088-39691 of SEQ ID NO:15; h) nucleotides 35057-35139 and 38088-39691 of SEQ ID NO:15 or i) nucleotides 33958-34062 and 38088-39691 of SEQ ID NO:15. An isolated nucleic acid molecule having a nucleotide sequence as set forth in SEQ ID NO:12; SEQ ID NO:16; SEQ ID NO:17 or SEQ ID NO:18 is useful as an oligonucleotide primer. A method for screening for possibility of a testicular seminoma, non-small cell lung carcinoma, melanoma-1 breast cancer, sarcoma or leukemia in a sample, comprises: contacting the sample with at least one nucleic acid molecule which hybridizes to mRNA corresponding to an MAGE-Xp gene, and then determining hybridization as a determination of possible presence of testicular seminoma, non-small cell lung carcinoma, melanoma, breast cancer, sarcoma or leukemia in the sample. A method for determining presence of leukemia, lymphoma, head and neck squamous cell carcinoma, or mammary carcinoma in a sample, comprises: assaying the sample for mRNA for MAGE-B2, wherein presence of the mRNA is indicative of possibility of leukemia, lymphoma, head and neck squamous cell carcinoma, or mammary carcinoma in the sample. A method for determining presence of skin carcinoma mammary carcinoma, comprises: assaying a sample for presence of mRNA for MAGE-B1 gene, wherein presence of the  mRNA is indicative of possibility of skin carcinoma or mammary carcinoma in the sample.
PROBLEM TO BE SOLVED: To provide a new glycoprotein consisting of a glycoprotein having respectively specific contents of carbohydrate and chlorine ion and a specific molecular weight, having antiviral activity, free from side action and useful for the prophylaxis, treatment, etc., of the infection with virus such as influenza virus. SOLUTION: This new glycoprotein contains about 17.5 wt.% of carbohydrates, about 21.5 wt.% of proteins and about 28.6 wt.% of chlorine ion and has a molecular weight of about 7×10&lt;3&gt; wherein the mol.% of the constituent sugars are about 71.8 for glucose, about 11.0 for galacturonic acid, about 8.1 for glucuronic acid, about 3.9 for galactose, about 2.6 for mannose, about 1.4 for arabinose and about 1.3 for rhamnose. It is useful e.g. as an agent having antiviral action, free from side effect and effective for the treatment and prophylaxis of infection with virus such as influenza virus.  The glycoprotein can be produced by adding refined water to Banrankon (root of Isatis tinctoria, etc.), decocting for about 3 hr, filtering the product, concentrating the filtrate, adding ethanol to the concentrated filtrate, filtering the formed precipitate, drying the precipitate, dissolving the dried material in an aqueous solution of Nail and purifying by gel-filtration.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncology and can be used for treatment of pulmonary cancer. Essence of invention lies in the fact that before initiation of treatment an extracorporeal ray treatment of 300 ml of patient&#39;s blood in red diapason range with =0.67 mcm in continuous-wave mode during 3 minutes at maximum radiant power 17 mlW, radiation level w=3.06 J/cm2 is conducted. Then irradiated blood is incubated with cytostatic in therapeutic dose during 40 minutes at T=37C, whereafter the irradiated blood with cytostatic is inserted to patient intravenously by drop infusion. During course of treatment three or four such procedures are conducted at three days interval, in total one or two courses of treatment at three weeks interval are conducted. ^ EFFECT: use of this invention enables to transfer patients with tumors of stage three or four into resectable condition by means of stimulating involution and regress of neoplastic deposits from lymphonodus at neoadjuvant therapy delivery of photo- modified autoblood. ^ 2 ex
The invention relates to the fields of biotechnology, virology, epidemiology and public health, and is method for obtaining of new inactivated vaccine against coronavirus COVID-19. The essence matter of invention is COVID-19 virus &#34;SARS-CoV-2/KZ_Almaty/04.2020&#34; strain isolated on the territory of the Republic of Kazakhstan. The strain of COVID-19 virus according to the optimal cultivation conditions is produced in the Vero cell culture system, inactivated by formaldehyde, clarified by low-speed centrifugation, purified and concentrated by diafiltration on diafiltration unit of Millipore Pellicon Cassette system. Sterilizing filtration is carried out through cascades of filters with a pore diameter of 0.45/0.22 μm. 2 % aluminum hydroxide gel &#34;Algidrogel, 85&#34; is added in the obtained virus pool (viral concentrate) to final concentration of 0.5 mg/0.5 ml and bottled in glass vials. The vaccine obtained in this way is safe at intraperitoneal introduction to white mice and intravenously - to rabbits. The vaccine provides 80 % protection against COVID-19 infection for at least 6 months after two vaccinations. The vaccine keeps its properties for 12 months at 4-6°C.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for prophylaxis and/or treatment of progress of symptom by immunostimulation to immunity-related diseases causing lowering of immunity.  &lt;P&gt;SOLUTION: The composition for stimulating immunity comprises a component derived from germinated sesame as an active ingredient for immunostimulating action, more particularly immunostimulating action by activation action of macrophage. The composition is used for preventing or treating immunity-related diseases caused by lowering of immunoreactivity. The composition has a form selected from a group consisting of a food material, a beverage or food, a health beverage or food, a medicine and a feed. The immunostimulating method comprises utilizing immunostimulating effect of a component derived from germinated sesame in order to prevent and/or treat immunity-related diseases caused by lowering of immunity.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A measurement support system includes a measurement device and a management device connected to the measurement device via a communications network. When the measurement device uses consumable materials such as reagents, the management device manages the stock of consumable materials, supplies the consumable materials, and corrects measured data in accordance with the state of the consumable materials. Thus, the measurement support system can reduce the burden on users of the measurement device. The reagents that are used in measurement by a personal measuring instrument ( 3 ) located at each of patients&#39; homes (B, C, . . . ) are assigned a reagent ID number beforehand. This reagent ID number and measured data are transmitted to a host computer ( 1 ) of a medical institution (A). The host computer ( 1 ) determines the stock of reagents based on the consumable material identifier received from the personal measuring instrument ( 3 ) and ships the reagents to the patient&#39;s home when the stock is running low. The host computer ( 1 ) also corrects the measured data in view of a calibration curve and degradation based on the production lot information of the reagents stored in correspondence with the reagent ID number.
The present invention deals with new radiopharmaceuticals for renal studies with ligands labelled with technetium- 99m. The ligands have the general formula: &lt;IMAGE&gt; where X and Y are NH, O or S and can be substituted in the N1 position by methyl, phenyl and phenethyl groups. The present invention indicates how to prepare these new compounds labelled with technetium-99m. In the case of the unsubstituted ligand and when X = Y = NH, the substance is biguanide. This ligand, when labelled with technetium-99m, is preferentially eliminated by the kidneys, having an elimination kinetics favourable to renal diagnostic studies. Tests in laboratory animals show that biguanide labelled with technetium-99m presents advantages from the standpoint of clinical practice and lower radiation dose than a currently used radiopharmaceutical, dimercaptosuccinic acid, DMSA.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an excellent oxidation stress inhibitor and an immunostimulator which have high safety.  &lt;P&gt;SOLUTION: The oxidation stress inhibitor and the immunostimulator use at least one of uridylic acid, uridine and uracil as an active ingredient. Various actions of IgA antibody production promotion, SOD (superoxide dismutase) activity enhancement, lipid peroxide inhibition and IFN-γ production promotion are exemplified as their concrete actions. The agents are useful as foods and beverages and feeds besides medicines. The use objects widely include human and animals (livestock, poultry, pet, and the like) except human. The method for preventing and/or treating oxidation stress, and the like, comprises administration of the active ingredient.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain an extract of pancreas having specific properties and actions on prevention of fatty stool and diarrhea of newborn, especially low-weight newborn, elderly person reduced in function of internal organ, patient of internal organ, etc., by treating the supernatant liquid of a homogenized substance of pancreas with an acid. SOLUTION: The supernatant liquid of a homogenized substance of pancreas is treated with an acid or a buffer solution and allowed to stand at pH4-5 for a moment to give the objective extract of pancreas having the following properties. (A) The extract has lipase activity and raises its activity by the presence of bile acid. (B) The extract has esterase activity and raises its activity by the presence of bile acid. (C) The lipase activity and the esterase activity are stable at pH &lt;9 and the activities are lowered at pH &gt;=9. (D) The extract contains a protein having 10,000-100,000 molecular weight. (E) The extract comprises 60-70g protein based on 100g of the extract (dried substance). (F) The extract contains 10-15g of glucide based on 100g of the extract (dried substance).
A four-week randomized clinical trial will involve 18 participants, divided randomly into two intervention groups, with nine participants in each group. Group A (intervention group 1) will participate in Swiss ball exercises combined with stretching, while Group B (intervention group 2) will partake in Frenkel exercises along with stretching. The sampling method employed will be a non-probability technique. The Pediatric Balance Scale (PBS) will serve as the primary tool for outcome measurement. Randomization will be conducted using computer-generated software. The study design will be single-blinded, ensuring the assessor remains unaware of the groups\&#39; assignments. Initial data collection (pretest) will occur at week 0, followed by post-test data collection at week 4. For intergroup analysis, if the data follows a normal distribution, the parametric Independent t-test will be utilized, enabling the calculation of mean, standard deviation, and p-values. Alternatively, if the data does not display a normal distribution, the non-parametric Mann-Whitney test will be employed, allowing the calculation of median, interquartile ranges, and p-values.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method of manufacturing improved keratin which can suitably perform application to a cosmetic, a medical product or the like.  &lt;P&gt;SOLUTION: The method of manufacturing improved keratin includes the followings. The keratin as a raw material added with a mineral is fermented, subsequently the fermentation keratin is mixed with an organic acid and is ripened. Concretely, the raw material keratin is added with a mineral and steamed by sanitized water of a prescribed amount, then is added with aspergillus or the like and is fermented. The fermentation keratin is mixed with an organic acid mixture of citric acid or the like which has a carboxyl group, is held at a predetermined temperature, is ripened, and is filtration-extracted. According to the method of manufacturing, as for a dispersion liquid of the raw material keratin, an oxygen bond is cut by a fermentation action of aspergillus or the like, further a bivalent mineral suitably combines with a monomer unit terminal of the cut keratin and the status is held, thereby the keratin which can be applied to a cosmetic, a medical product or the like can be efficiently manufactured by a low molecular weight compared with conventional one.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a liposome having high imaging ability for a lesion part, including a gas or a droplet efficiently encapsulated therein, and exhibiting excellent therapeutic effects in a heating and coagulating therapeutic method (a method by high intensity focused ultrasound).  &lt;P&gt;SOLUTION: The liposome includes biocompatible micelles including perfluorohydrocarbon. The perfluorohydrocarbon in the inside of the micelle is, for example, perfluoro-n-pentane. The surface of the liposome is modified with transferrin. Doxorubicin is included in the interior of the liposome as a sonochemistry activator.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain the new subject compound having extremely excellent lubricating properties, exhibiting excellent compatibility with most of solvents, capable of uniformly dispersing in water, useful for a base, emulsifier, etc., for hair cosmetic and skin cosmetic and capable of simply and inexpensively synthesizing. CONSTITUTION:A branched fatty acid amide of formula I (R&lt;1&gt; and R&lt;2&gt; are 2-24C straight chain alkyl, with the provide so that total carbon number of R&lt;1&gt; and R&lt;2&gt; is 4-26), e.g. N-tris(hydroxymethyl)methyl-alpha-octylarachidic amide. The compound is obtained by reacting a branched fatty acid of formula II with an equimolar tris(hydroxymethyl)aminomethane of formula III to afford an oxazoline derivative of formula IV and then hydrolyzing the oxazoline derivative. The reaction of the compound of formula II with the compound formula III is preferably carried out at 50-200 deg.C for 1-130hr while removing produced water. The hydrolysis reaction is preferably carried out in water or a mixed solution of water and 1-6C alcohol at 70-120 deg.C. Furthermore, the intermediate of formula IV is a new compound.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a specific binding member binding human ED-B, containing an antigen-binding part comprising an antibody VH domain and an antibody VL domain.  &lt;P&gt;SOLUTION: Provided are selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 having the variable regions of L19 is employed. In other embodiments a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer is employed. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Actin-free myosin is separated from intimate association with polymerized actin in muscle material, e.g. raw muscle, actomyosin which may be prepared according to Specification 745,715, &#34;myosin B&#34;, by heating the material, which has been substantially freed from adenosine triphosphate, with an aqueous salt solution which comprises an alkali metal iodide or thiocyanate, e.g. sodium or potassium salt, at a temperature below 10 DEG  C., and diluting the extract with water to a salt concentration of below 0.05 M to precipitate the myosin.  If the starting material contains adenosine triphosphate, e.g. fresh raw muscle, it is washed with a solvent, e.g. water, dilute aqueous potassium chloride, or potassium chloride and phosphate solutions, to remove substantially all the adenosine triphosphate e.g. to a concentration of less than 10-5 M, prior to the extraction of the actin and myosin with a solution of the salt of concentration between 0.4 and 0.8 M.
A hair care composition comprises: (i) a water soluble ester of formula RCOXR&#39;, wherein R is an optionally substituted alkyl, alkenyl or aryl group including a hydrocarbyl group of at least 5 carbon atoms; R&#39; includes a water solubilising group; and X is O, S or NR&#34;, wherein R&#34; ishydrogen or an alkyl group; and (ii) an oil. Component (i) may comprise a polysorbate, such as polysorbate 80. Preferably the oil is a plant oil selected from olive oil, coconut oil, and sweet almond oil. Component (i) may be present at from 20 to 50wt%. The composition may comprise a silicone such as PEG-12 dimethicone. A method of treating hair comprises contacting the hair with the composition, and may be carried out prior to shampooing.